A Phase 1 interventional study of Test: Follitropin alfa and Reference: Follitropin alfa in Hypogonadism, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.
Among the 185 studies in Hypogonadism with a site in United States, this one is the 71st largest by enrollment of the 154 interventional ones that give a count, is one of 5 that started in 2025, is one of 29 in phase 1, and was the 183rd registered.
320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.
Browse Hypogonadism studies →12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:
Stephanie B. Seminara, MD · Sites in United States
Ages 18–45 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Men only
Halozyme Therapeutics · Sites in United States
Ages 12–17 · Men only
Bradley Nindl · Sites in United States
Ages 18–40 · Healthy volunteers
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 62 · Phase 3 31 · Phase 4 27
First in 1989; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is close to the median of 50 across 243 interventional studies indexed under Hypogonadism.
Median enrollment 45 across the 154 interventional studies, 70 across the 27 observational. Of the 154 that completed or were terminated, 84 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 185 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
Merck KGaA, Darmstadt, Germany has 3 studies filed under Hypogonadism — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypogonadism with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04301765Seattle Institute for Biomedical and Clinical ResearchImproving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency | 2026-11 |
| NCT06720597University of California, IrvineEndoPAT Device for Endothelial Dysfunction in ED | 2027-01 |
| NCT04049331Seattle Institute for Biomedical and Clinical ResearchTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | 2027-01-30 |
| NCT06455969Bradley NindlAdaptions and Resiliency to Multi-Stressor OpeRations | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 185 studies in Hypogonadism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the bioequivalence of Test and Reference in healthy downregulated male participants. This is a 2-sequence, 2-period study using the following treatment sequences across Study Periods 1 and 2. At the end of the first Downregulation period (DR1), eligible participants will be randomly assigned to 1 of the 2 treatment sequences:
Sequence 1: Test - Reference Sequence 2: Reference - Test Where, Test = follitropin alfa (solution for injection in prefilled pen), and Reference = follitropin alfa (powder and diluent for solution for injection in vial).
The total duration of the study will be up to approximately 9 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants using the following within 28 days prior to start of study intervention:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Test follitropin alfa in Period 1 followed by Reference follitropin alfa in Period 2.
Combination Product: Test: Follitropin alfa · Drug: Reference: Follitropin alfa · Drug: Zoladex
Participants will receive reference follitropin alfa in Period 1 followed by test follitropin alfa in Period 2.
Combination Product: Test: Follitropin alfa · Drug: Reference: Follitropin alfa · Drug: Zoladex
It is a solution for injection in prefilled pen. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of at least 23 days will be maintained between period 1 and 2.
It is a powder and diluent for solution for injection in multidose vial. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of 23 days will be maintained between period 1 and 2.
It is a auxiliary medicinal product. Participants will receive Zoladex injection on Day -11 in down regulation period, and on Day 17 prior to the start of Period 2.
Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Sampling Time After Administration (AUC0-t, adj) of Follitropin Alfa
Time frame: Predose at -45, - 30, -15 minutes, and at 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, (Day 1), 24 and 36 hour (h) (Day 2), 48 h (Day 3), 72 h (Day 4), 96 h (Day 5), 120 h (Day 6), 168 h (Day 8) and 216h (Day 10) after Test/Reference administration
Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC0-inf,adj) of Follitropin Alfa
Time frame: Predose at -45, - 30, -15 minutes, and at 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, (Day 1), 24 and 36 hour (h) (Day 2), 48 h (Day 3), 72 h (Day 4), 96 h (Day 5), 120 h (Day 6), 168 h (Day 8) and 216h(Day 10) after Test/Reference administration
Baseline Adjusted Maximum Observed Serum Concentration (Cmax,adj) of Follitropin Alfa
Time frame: Predose at -45, - 30, -15 minutes, and at 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, (Day 1), 24 and 36 hour (h) (Day 2), 48 h (Day 3), 72 h (Day 4), 96 h (Day 5), 120 h (Day 6), 168 h (Day 8) and 216h(Day 10) after Test/Reference administration
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to Day 37
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) by Severity
Time frame: Up to Day 37
Occurrence of Abnormalities (Grade >=3) in Laboratory Test Values
Time frame: Up to Day 37
Occurrence of Abnormalities (Grade >=3) in Vital Signs
Time frame: Up to Day 37
Occurrence of Clinically Significantly Abnormal Electrocardiograms (ECGs)
Time frame: Up to Day 37
Number of Participants With Local Tolerability/Injection Site Reactions (ISRs)
Time frame: Up to Day 37
Pharmacokinetic (PK) Plasma Concentrations of Follitropin Alfa
Time frame: Predose at -45, - 30, -15 minutes, and at 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, (Day 1), 24 and 36 hour (h) (Day 2), 48 h (Day 3), 72 h (Day 4), 96 h (Day 5), 120 h (Day 6), 168 h (Day 8) and 216h(Day 10) after Test/Reference administration
Number of Participants With Positive Anti-Drug Antibody (ADA) of Follitropin Alfa
Time frame: Predose: Day 1 (Period 1), Day 28 (Period 2), Day 37 (End of Treatment). ADA positive participants followed until end of study(earliest of ADA negative(baseline) or loss to follow-up (upto 40 months)
Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
Of 13 phase 1 interventional studies under Hypogonadism, half reached primary completion within 32 months of starting (the median); a quarter within 18 and three quarters within 57. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
EMD Serono Research & Development Institute, Inc. →